Space startup Varda raises $187 million in funding to make drugs in orbit

Space startup Varda raises 7 million in funding to make drugs in orbit


Pavlo Gonchar | Lightrocket | Getty Images

Space startup Varda announced on Thursday that it has raised $187 million in Series C funding, led by venture capital firms Natural Capital and Shrug Capital, to continue advancing drug manufacturing in space.

The latest round included participation from Peter Thiel, Lux Capital, Khosla Ventures and Caffeinated Capital. It brought the total capital Varda’s raised to $329 million.

“By expanding, we can support work on more complex molecules and ultimately increase cadence to achieve the turnaround times the pharmaceutical industry expects,” Chief Science Officer Adrian Radocea said in a press release Thursday.

Varda’s main mission is to launch and return drugs made in space. The startup has said the medicines crystallize differently in orbit due to the gravity differences, which would allow it to complete drugs that are currently difficult to manufacture.

In 2024, the space startup’s W-Series 1 capsule received FAA approval to return after successfully creating the drug Ritonavir the previous year.

So far, Varda said the company has been able to complete three space launches. Now, a fourth is in orbit, and the company expects to launch a fifth by the end of the year. Varda’s system uses Rocket Lab’s Photon spacecraft for its operation and adds its manufacturing module and a heatshield-protected capsule.

“With this capital, Varda will continue to increase our flight cadence and build out the pharmaceutical lab that will deliver the world’s first microgravity-enabled drug formulation,” said Varda CEO Will Bruey.

Varda Space Industries is the first company to process materials outside the International Space Station.

Recently, the space company has also operated a testbed for the U.S. government to use the W-series reentry vehicles to advance technology.

Varda said it has expanded into Huntsville, Alaska, and opened a laboratory in El Segundo, California, to begin work to crystallize more drugs.

“Our new lab space is an investment in our belief that in-space pharmaceutical manufacturing will drive the foundation of the orbital economy,” Radocea said.



Source

Big Food gets leaner with divestitures and breakups as consumers turn away from packaged snacks
Business

Big Food gets leaner with divestitures and breakups as consumers turn away from packaged snacks

Kraft Heinz announced plans to split into two separately traded companies, reversing its 2015 megamerger, which was orchestrated by billionaire investor Warren Buffett. Justin Sullivan | Getty Images News | Getty Images Big Food is slimming down. As both consumers and regulators push back against ultra-processed foods, the companies that make them have been splitting […]

Read More
Eli Lilly CEO says Medicare coverage of obesity drugs could ‘change the game’ for upcoming pill launch
Business

Eli Lilly CEO says Medicare coverage of obesity drugs could ‘change the game’ for upcoming pill launch

Eli Lilly CEO Dave Ricks on Friday said upcoming Medicare coverage of obesity drugs could be a major catalyst for the rollout of the company’s closely watched experimental weight loss pill, orforglipron. In an exclusive interview with CNBC, Ricks said Lilly expects to have Medicare coverage for the treatment “immediately following that launch, and that […]

Read More
GameStop’s Ryan Cohen eyes ‘very big’ consumer megadeal that could increase company’s value tenfold
Business

GameStop’s Ryan Cohen eyes ‘very big’ consumer megadeal that could increase company’s value tenfold

GameStop wants to acquire a publicly traded consumer company that’s far larger than the video game retailer in a deal that could be “transformational” for the company, CEO Ryan Cohen told CNBC in an interview Friday. “It’s gonna be really big. Really big. Very, very, very big,” Cohen said of the size of the acquisition. […]

Read More